3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
April 2022 in “Reactions Weekly” March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
August 2022 in “Dermatologic Therapy” November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
March 2019 in “Reactions Weekly”
4 citations
,
September 2022 in “Indian Journal of Pharmaceutical Education and Research” Plumbago zeylanica L. leaves may help dissolve blood clots and have antioxidant benefits.
January 2007 in “Pharmaceutical Journal of Chinese People's Liberation Army” The two finasteride tablets are bioequivalent.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
6 citations
,
August 2021 in “International Journal of Pharmaceutics” A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
January 2026 in “Journal of Ayurveda and Integrated Medical Sciences” Bhringaraj extract tablets significantly reduce hair fall and are well-tolerated.
1 citations
,
January 2003 in “Zhongguo yaoke daxue xuebao” The two finasteride tablet formulations are bioequivalent.
December 2022 in “Small methods” A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.